Sentences with phrase «approved targeted therapy»

Importantly, without any prior knowledge from the analysis of tumor tissue, 76 % of «actionable» mutations (genetic changes that can be matched to an approved targeted therapy or one being tested in clinical trials) detected in tissue were also detected in blood.

However, on page 1391 in this issue, Yun et al. (5) show that high doses of vitamin C selectively kill colorectal cancer cells carrying activating mutations in the oncogenes KRAS or BRAF, which are often refractory to approved targeted therapies.

Professor Jean - Charles Soria, Chairman of the Drug Development Department at Gustave Roussy Cancer campus, France, will tell the Symposium: «Currently, there are no approved targeted therapies for mutant EGFR lung cancer patients who develop the T790M mutation, which means their disease inevitably will get worse.

TNBC is the only type of breast cancer for which there are no currently approved targeted therapies.

Not exact matches

No targeted therapy has been approved for noninflammatory and inflammatory triple - negative breast cancer tumors, and the standard of therapy for these tumors is a combination of conventional cytotoxic chemotherapeutic agents.

«Rare genetic cause of peritoneal mesothelioma points to targeted therapy: Genetic rearrangement in the ALK gene found in young women with mesothelioma may be targetable with FDA - approved drugs.»

«Inhibiting mTOR signaling using everolimus, a targeted therapy, known as a rapalog, for patients with lung and gastroenteropancreatic NETs, has been approved by the FDA.

The researchers were able to reverse these epigenetic changes with the use of an FDA - approved drug, forcing the cancer cells out of hiding and potentially making them better targets for the same immune therapy that in the past may have failed.

A drug approved in Europe to treat osteoporosis has now been shown to stop the growth of breast cancer cells, even in cancers that have become resistant to current targeted therapies, according to a Duke Cancer Institute study.

«By helping us understand that lower levels of RNF125 confer resistance to BRAF inhibitors, we have a new strategy to stratify patients for currently approved therapy versus participation for human clinical trials to investigate whether targeting JAK1 will be more effective in patients whose tumors exhibit reduced RNF125,» said Keith T. Flaherty, M.D., associate professor, Harvard Medical School, and director of Developmental Therapeutics, Cancer Center, Massachusetts General Hospital, and co-author of the study.

Luxturna is the first gene therapy approved in the U.S. that targets a disease caused by mutations in a specific gene.

Genomic alterations were reviewed by the Institute's molecular tumor board and recommendations for patient treatment options were made regarding genomically targeted therapies either already approved or used investigationally — including clinical trials.

The targeted antibody bevacizumab (Avastin ®) is already approved for ovarian cancer patients, and a number of immune - based therapies are being investigated in early - phase clinical trials for patients with ovarian cancer.

Currently, immunotherapy is approved by the Food and Drug Administration (FDA) to treat kidney cancer patients only after they've tried more traditional therapies, such as targeted therapies killing the cancer's blood supply.

Hopefully, there will be another regimen approved which is a targeted therapy, only for melanoma patients who have a BRAF mutation.

However, for the majority targeted therapies in development — and their combinations with current standard therapies — there are still no approved diagnostic tools to determine which patients are most likely to benefit from or be resistant to these novel agents or drug combinations.

Several targeted therapies have been approved by the FDA for use in advanced kidney cancers, including the anti-VEGF antibody bevacizumab (Avastin ®), the cytokine aldesleukin (Proleukein ®), and the anti-PD-1 checkpoint inhibitor nivolumab.

It has been generally surmised that intralesional therapies will be combined with the successful systemic immunotherapies — the checkpoint inhibitors or targeted therapies already approved or in development.

With the currently approved FDA cancer therapeutics drugs, we are only targeting the tip of the iceberg (85 targeted therapies for 105 gene products (1)-RRB- and with over 22,000 genes in our genome many genes are being neglected!

Although recently approved therapies can increase progression - free survival by a few months, «we think this novel screening system has the potential to uncover new, more effective medications that could be targeted more specifically at a patient's cancer,» Lengyel said.

In this regard, Roberts indicates that «In 2005, the U.S. Food and Drug Administration approved the first race - specific drug, a heart failure therapy that was targeted to black patients for marketing reasons.»